Atopic Dermatitis

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.

These new findings were released by Eli Lilly and presented at the European Academy of Dermatology & Venereology Congress.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

The FDA decision to accept the new drug application for delgocitinib cream is also occurring alongside the drug’s acceptance by the European Commission.

Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.

Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis.

In this segment of his interview, Zirwas highlighted the use of JAK inhibitors such as upadacitinib, discussed safety, and touched on topical options for patients with eczema.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients.